<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227509</url>
  </required_header>
  <id_info>
    <org_study_id>CONPELAN</org_study_id>
    <nct_id>NCT04227509</nct_id>
  </id_info>
  <brief_title>Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase II Study of CONsolidation PEmbrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with
      cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of
      pembrolizumab until disease progression or recurrence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II multi-center, randomized controlled trial of consolidation pembrolizumab after
      chemoradiotherapy in locally advanced nasopharyngeal carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year progression-free survival (PFS) rate</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response rate (RR)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline will be administered as a 30 minute IV infusion every 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically diagnosed nasopharyngeal carcinoma(NPC)

               1. WHO Type 2a, 2b nonkeratinizing, undifferentiated subtype

               2. Keratinizing subtype is excluded due to less associated with EBV infection

          2. Stage II-IVB Locally advanced disease

             a. Stage II-IVB disease must confirmed by initial CT and/or MRI, PET CT at initial
             diagnosis according to the AJCC 8th edition

          3. Prior Therapy

               1. Patients must have received curative radiotherapy (radiation dose ≥ 60Gy) and
                  concurrent cisplatin (cumulative dose ≥ 200mg/m2)

               2. Induction chemotherapy followed by CCRT is permissible

               3. CCRT followed by adjuvant FP is permissible

               4. Patients must have recovered Gr2 or less than Gr2 from all acute, reversible
                  toxic effects from chemotherapy and radiotherapy (excluding alopecia)

          4. Age 19 or more than 19 years old

          5. The patient must have an ECOG performance status of 0, 1

          6. Patients must be accessible for treatment and follow-up. Investigators must assure
             themselves the patients randomized on this trial will be available for complete
             documentation of the treatment, adverse events, and follow-up.

          7. patient with the willingness to comply with the study protocol during the study period
             and capable of complying with it

          8. A patient who signed the informed consent prior to the participation of the study and
             who understands that he/she has a right to withdrawal from participation in the study
             at any time without any disadvantages. Patient consent must be appropriately obtained
             in accordance with applicable local and regulatory requirements. Each patient must
             sign a consent form prior to enrolment in the trial to document their willingness to
             participate.

          9. Have adequate organ function as defined in the following . Specimens must be collected
             within 10 days prior to the start of study treatment.

        Hematological Absolute neutrophil count (ANC) ≥1500/µL Platelets ≥100 000/µL Hemoglobin
        ≥9.0 g/dL or ≥5.6 mmol/La Renal Creatinine ≤1.5 × ULN OR Measured or calculatedb creatinine
        clearance (GFR can also be used in place of creatinine or CrCl) ≥30 mL/min for participant
        with creatinine levels &gt;1.5 × institutional ULN Hepatic Total bilirubin ≤1.5 ×ULN OR direct
        bilirubin ≤ULN for participants with total bilirubin levels &gt;1.5 × ULN AST (SGOT) and ALT
        (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases) Coagulation
        International normalized ratio (INR) OR prothrombin time (PT) Activated partial
        thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy
        as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

        Exclusion Criteria:

          1. Participants are excluded for patients with a history of other malignancies

             a. except: adequately treated non-melanoma skin cancer, early gastric cancer,
             curatively treated in-situ cancer, or other solid tumors curatively treated with no
             evidence of disease for ≥ 5 years following the end of treatment and, which, in the
             opinion of the treating physician, do not have a substantial risk of recurrence of the
             prior malignancy.

          2. History of autoimmune disease, including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis.

             a. Patients with Grave's disease and/or psoriasis not requiring systemic therapy
             within the last two years from randomization are not excluded.

          3. History of primary immunodeficiency, history of organ transplant that requires
             therapeutic immunosuppression and the use of immunosuppressive agents within 28 days
             of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity
             from other immune therapy.

               1. Intranasal/inhaled corticosteroids or systemic steroids that do not to exceed 10
                  mg/day of prednisone or equivalent dose of an alternative corticosteroid are
                  permissible.

               2. pneumonitis that has required a course of oral steroids to assist with recovery,
                  or a history of interstitial lung disease

          4. History of diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction,
             abdominal carcinomatosis which are known risks factors for bowel perforation

          5. Live attenuated vaccination administered within 30 days prior to randomization.

          6. History of severe hypersensitivity (≥Grade 3) to pembrolizumab

          7. Mean QTc correction &gt; 470msec in screening ECG measured using standard institutional
             method or history of familial long QT syndrome.

          8. Patients who have experienced untreated and/or uncontrolled cardiovascular conditions
             and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart
             failure, myocardial infarction within the previous year or cardiac ventricular
             arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular
             conduction defects). Patients with a significant cardiac history, even if controlled,
             should have a LVEF &gt; 50% within 12 weeks prior to randomization.

          9. Concurrent treatment with other investigational drugs or anti-cancer therapy.

         10. Patients with active or uncontrolled infections or with serious illnesses or medical
             conditions which would not permit the patient to be managed according to the protocol.
             This includes but is not limited to:

               1. known active tuberculosis (inactive tuberculosis or tuberculosis scar are
                  allowed)

               2. known acute hepatitis B or C by serological evaluation (inactive healthy HBsAg
                  carriers treated with pre-emptive anti-viral agents were allowed)

               3. known human immunodeficiency virus infection.

         11. Active symptomatic central nervous system (CNS) metastases that the disease also has
             to have demonstrable stability with no evidence of growth and has not required recent
             steroid use and/or carcinomatous meningitis

         12. Active infection requiring therapy

         13. Symptomatic ascites or pleural effusion

         14. Pregnant or lactating women. Women of childbearing potential must have a urine
             pregnancy test proven negative within 14 days prior to randomization. Men and women of
             child-bearing potential must agree to use adequate contraception as described in
             protocol

         15. Prior organ transplant or allogeniec bone marrow transplant regardless of whether
             immunosuppressive therapy has been used in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bhumsuk Keam, Ph.D.</last_name>
    <phone>82220727215</phone>
    <email>bhumsuk@snu.ac.kr</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bhumsuk Keam</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

